Leigh Syndrome
https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0332283
This study reports the results of a phase III clinical trial testing SPP‑004, a combination of 5‑aminolevulinic acid (5‑ALA) and sodium ferrous citrate, as a potential treatment for Leigh syndrome, a severe mitochondrial disorder that causes progressive neurological decline in children. Because no approved medication exists for Leigh syndrome, researchers evaluated whether SPP‑004 could help maintain clinical improvements in patients who initially responded well to the drug. Fifty‑four patients first received SPP‑004 for 24 weeks. Of these, 28 showed improvement in neurological or muscle‑related symptoms and entered a 48‑week double‑blind phase, where they were randomly assigned to continue SPP‑004 or switch to placebo. A placebo is a medicine with no active medicine that is often used in research as a control to compare against the real treatment. A double-blind study is where neither the researcher nor patient know which medicine the patient is assigned. The main outcome was whether patients lost their initial improvement. The study found that the number of patients who stopped at 48 weeks due to no or lost improvement was lower in the SPP‑004 group (15.4%) compared to the placebo group (50.0%). More than 80% of patients on SPP‑004 maintained their clinical benefit. Safety results were encouraging; adverse drug reactions were mild and side‑effect rates were similar between groups. Overall, the trial suggests that SPP‑004 may help sustain neurological improvements in Leigh syndrome and is generally safe, it represents a promising step toward developing targeted therapies for this devastating mitochondrial disease.